Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix.

被引：0
|
作者：
Ghamande, Sharad A.
Dobbins, Robin
Marshall, Lisa
Wheatley, Donna
Prince, Cheryl
Mauro, David J.
Janik, John Edward
Khleif, Samir
机构：
[1] Georgia Regents Univ, Augusta, GA USA
[2] Georgia Reagents Univ, GRU Canc Ctr, Augusta, GA USA
[3] Advaxis Inc, Princeton, NJ USA
[4] Georgia Hlth Sci Univ, Ctr Canc, North Augusta, GA USA
[5] Georgia Regents Univ, Ctr Canc, Augusta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps3096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3096
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study evaluating high-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer.
    Ghamande, Sharad A.
    Platt, Daniel
    Wheatley, Donna
    Rungruang, Bunja Jane
    Janik, John Edward
    Khleif, Samir
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] ADXS11-001, mitomycin, 5-FU and radiation for anal cancera A phase I/II study
    Safran, Howard
    Perez, Kimberly
    Klipfel, Adam
    Shah, Nishit
    Vrees, Matthew
    Dipetrillo, Thomas
    Austin, T.
    Jean, Maureen
    Luppe, Denise
    Rosati, Kayla
    SEXUAL HEALTH, 2013, 10 (06) : 588 - 588
  • [3] A phase II study of live-attenuated Listeria monocytogenes immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265)
    Huh, Warner King
    Brady, William E.
    Moore, Kathleen N.
    Lankes, Heather A.
    Monk, Bradley J.
    Aghajanian, Carol
    Dizon, Don S.
    Fracasso, Paula M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] A phase 2 study of live-attenuated listens monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265).
    Huh, Warner King
    Brady, William E.
    Moore, Kathleen N.
    Lankes, Heather A.
    Monk, Bradley J.
    Aghajanlan, Carol
    Dizon, Don S.
    Armstrong, Deborah K.
    Thaker, Premal H.
    Fracasso, Paula M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal.
    Fakih, Marwan
    O'Neil, Bert H.
    Chiorean, E. Gabriela
    Hochster, Howard S.
    Chan, Emily
    Mauro, David J.
    Eng, Cathy
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer
    Slomovitz, B.
    Bradley, W. H.
    Ghamande, S.
    O'Malley, D. M.
    Huang, M.
    Chon, H. S.
    Vangala, S.
    Sheeri, S.
    Gutierrez, A. A.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 4 - 5
  • [7] FINAL RESULTS FROM A PHASE-II RANDOMIZED CONTROLLED STUDY EVALUATING ADXS11-001 IMMUNOTHERAPY TARGETING HPV-E7 IN WOMEN WITH RECURRENT/REFRACTORY CERVICAL CANCER
    Basu, Partha
    Petit, Robert
    Gupta, Sudeep
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 165 - 165
  • [8] A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
    Basu, Partha
    Mehta, Ajay
    Jain, Minish
    Gupta, Sudeep
    Nagarkar, Rajnish V.
    John, Subhashini
    Petit, Robert
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (04) : 764 - 772
  • [9] ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer.
    Basu, Partha
    Mehta, Ajay O.
    Jain, Minish Mahendra
    Gupta, Sudeep
    Nagarkar, Rajnish Vasant
    Kumar, Vijay
    Premkumar, Sumana
    Neve, Rakesh
    John, Subhashini
    Petit, Robert G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer
    Basu, Partha
    Petit, Robert G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345